COVID-19 mortality is strongly associated with the development of severe pneumonia and
acute respiratory distress syndrome with the worst outcome resulting in cytokine release …

Coronaviruses may activate dysregulated host immune responses. As exploratory studies
have suggested that interleukin‐6 (IL‐6) levels are elevated in cases of complicated Covid …

Background Evidence links COVID-19 severity to hyper-inflammation. Treatment with
tocilizumab, a monoclonal antibody directed against the interleukin-6 (IL-6) receptor, was …

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),
alsoknownasthe2019novelCoronavirus (2019-nCoV), has caused a recent outbreak of …

The identification of elevated IL-6 levels in patients with severe COVID-19 led to the rapid
development of clinical trials targeting this cytokine. Overall, these trials do not support the …

Abstract Interleukin-6 (IL-6), known as an inflammatory cytokine, can be involved in many
innate and adaptive immune responses. The role of IL-6 in the pathogenesis of the novel …

Introduction Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces a
dysregulated hyperinflammatory response. Areas covered Authors review evidence on IL-6 …

COVID-19 has emerged as a global pandemic. It is mainly manifested as pneumonia which
may deteriorate into severe respiratory failure. The major hallmark of the disease is the …

The epidemic due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
infection has been spreading globally, raising increasing concerns. This public health …

Abstract Background Interleukin-6 (IL-6) was proposed to be associated with the severity of
coronavirus disease 2019 (COVID-19). The present study aimed to explore the kinetics of IL …